Differences in Time to Disease Progression Do Not Predict for Cancer-specific Survival in Patients Receiving Immediate or Deferred Androgen-deprivation Therapy for Prostate Cancer: Final Results of EORTC Randomized Trial 30891 with 12 Years of Follow-up

Publication | Closed Access

DOI

Citations

References

2013

Year

Urs E. Studer, Peter Whelan, Florian Wimpissinger, J Casselman, Theo M. de Reijke, H Knönagel, Wolfgang Loidl, Santiago Isorna, S.K. Sundaram, Laurence Collette

European Urology

Androgen-deprivation TherapyUrologyGenitourinary CancerMedicineCancer ManagementClinical TrialsCancer PrognosisCancer-specific SurvivalProstatic DiseaseOncologyRadiation OncologyHealth Sciences